Why the study?
Emerging cancer immunotherapies increase cardiotoxicity risks and expand cardiovascular damage presentations, requiring cardio-oncological monitoring across pretherapeutic assessment, identification of impending toxicity, and post-therapeutic surveillance.
How can nuclear cardiology imaging techniques be used to monitor immunotherapy-related cardiotoxicity in cancer patients?
How can nuclear cardiology imaging techniques be used to monitor immunotherapy-related cardiotoxicity in cancer patients?
Nuclear cardiology provides promising molecular imaging techniques for the comprehensive cardio-oncological monitoring of immunotherapy-related cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to diverse immunotherapy cardiotoxicity in cancer patients; extends knowledge but leaves open prospective monitoring trials.
The emerging use of immunotherapies in cancer treatment increases the risk of immunotherapy-related cardiotoxicity. In contrast to conventional chemotherapy, these novel therapies have expanded the forms and presentations of cardiovascular damage to a broad spectrum from asymptomatic changes to fulminant short- and long-term complications in terms of cardiomyopathy, arrythmia, and vascular disease. In cancer patients and, particularly, cancer patients undergoing (immune-)therapy, cardio-oncological monitoring is a complex interplay between pretherapeutic risk assessment, identification of impending cardiotoxicity, and post-therapeutic surveillance. For these purposes, the cardio-oncologist can revert to a broad spectrum of nuclear cardiological diagnostic workup. The most promising commonly used nuclear medicine imaging techniques in relation to immunotherapy will be discussed in this review article with a special focus on the continuous development of highly specific molecular markers and steadily improving methods of image generation. The review closes with an outlook on possible new developments of molecular imaging and advanced image evaluation techniques in this exciting and increasingly growing field of immunotherapy-related cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Kersting et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: